Roche Reports Updated GO29781 Data for Lunsumio in Follicular Lymphoma

Roche today presented updated data from the Phase 2 GO29781 trial evaluating Lunsumio (mosunetuzumab-axgb) in patients with relapsed or refractory follicular lymphoma. The updated data showed that complete responses were durable, with 60% of patients who achieved a complete response remaining in remission at two years.